Patients with myasthenia gravis experience higher comorbidity rates and healthcare utilization compared to healthy controls, indicating a significant disease burden. Treatment patterns for ...
The Neuromuscular Disease Center has a long history of providing excellent clinical care and research in myasthenia gravis. Myasthenia gravis is a chronic autoimmune disorder that causes muscle ...
“This approval represents a major advancement in the treatment of pediatric myasthenia gravis and provides hope to families navigating this complex disease,” MDA chief research officer Sharon ...
Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...
Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue of voluntary muscles. Essentially, antibodies cause a breakdown in ...
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Myasthenia gravis is a serious, rare, and chronic neuromuscular autoimmune disease that can cause debilitating and potentially life-threatening muscle weakness. There are around 60,000 to 120,000 ...
Higher Quantitative Myasthenia Gravis-Revised (QMG) scores, indicating more severe disease based on clinician ratings, have been associated with frequent exacerbations. New data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback